News | May 02, 2024
Pfizer expects full-year 2024 revenues between US$ 58.5 to US$ 61.5 billion
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
Very strong revenue and EPS growth in the first quarter coupled with exciting pipeline delivery
Pemetrexed Injection is used as a drug, in the treatment of non-small cell lung cancer in combination with other chemotherapy agents
Global Phase-3 study initiation expected in the second half of 2024
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis
MoU to serve as the establishment of an Academic Collaboration in Ayurveda and Thai Traditional Medicine
Subscribe To Our Newsletter & Stay Updated
